Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers using its small molecule nucleotide platform. Co. is developing its product candidate, inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus. Co. has designed its antiviral product candidates, including inarigivir, to selectively activate within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1, to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The SBPH stock yearly return is shown above.
The yearly return on the SBPH stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SBPH annual return calculation with any dividends reinvested as applicable (on ex-dates).
|